vTv Therapeutics
Market cap $69.4M 4.0M shares (vendor count, Nov 18, 2026) × $17.29 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-15
- CATT1 Ph3 toplinemid-2027CATT1 Ph3 topline, mid-2027, major
- Cadisegliatin T2D Ph2 start2H 2027Cadisegliatin T2D Ph2 start, 2H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
TTP273
TTP-RA
mavodelpar
HPP593 · REN001- Undisclosed indication
HPP971
- Undisclosed indication
HPP737
- Undisclosed indication
HPPD
HPP8668Discontinued (1)
- azeliragon — Alzheimer's Disease · Phase 3 STEADFAST program terminated (NCT02080364 / NCT02916056 TERMINATED; NCT03980730 Phase 2 TERMINATED); the 10-Q carries azeliragon only under 'Other projects' with no development activity
Capital (as filed)
- Cash
- $77.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$10.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $77.2M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-17 UPDATE: vTv Therapeutics (VTVT) - A Seller Who Had No Choice 🔒 Paid
- 2026-11-06 UPDATE: vTv Therapeutics (VTVT) - Homework Done, Stock Down 28% ★ Distilled Pro
- 2026-10-09 UPDATE: vTv Therapeutics (VTVT) - Millennium Doubles Down ★ Distilled Pro
- 2026-10-06 UPDATE: vTv Therapeutics (VTVT) - The Clock Is Set 🔒 Paid
- 2026-08-07 UPDATE: vTv Therapeutics (VTVT) - The Gun They Didn't Fire 🔒 Paid
- 2026-05-14 UPDATE: vTv Therapeutics (VTVT) – The ATM Refresh on Earnings Day 🔒 Paid
- 2026-03-29 UPDATE: vTv Therapeutics (VTVT) - Smart Money Buys the Delay
- 2026-03-14 UPDATE: vTv Therapeutics (VTVT) – A Biotech Delay Hits Phase 3 🔒 Paid
- 2026-02-04 vTv Therapeutics (VTVT): Scientific Deep Dive for Cadisegliatin and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on vTv Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-04 Speculative buy speculative vTv Therapeutics (VTVT): Scientific Deep Dive for Cadisegliatin and Pipeline Products Hepatoselective chemistry addresses historical GKA toxicity, Phase 2 hypoglycemia benefit is the real value driver, and the company is fully funded to the binary Phase 3 readout in 2H 2026.
- 2026-03-14 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) – A Biotech Delay Hits Phase 3 Trial timeline slipped to 2027 but thesis is delayed not broken; balance sheet covers the extended runway and the hepatoselective chemistry conviction is unchanged.
- 2026-03-29 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - Smart Money Buys the Delay Millennium Management's 5% passive stake validates the runway math and confirms institutional confidence in the science despite the enrollment delay.
- 2026-05-14 Hold UPDATE: vTv Therapeutics (VTVT) – The ATM Refresh on Earnings Day ATM refresh signals potential dilution overhang and burn rate came in higher than modeled, making new entry unattractive until the ATM overhang clears or a tangible enrollment update arrives.
- 2026-08-07 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - The Gun They Didn't Fire Zero ATM shares sold in two consecutive quarters and enrollment on track for Q3 2026 removes the specific dilution overhang that triggered the May downgrade, restoring the speculative buy stance.
- 2026-10-06 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - The Clock Is Set CATT1 fully enrolled at 166 patients with topline now pinned to mid-2027; enrollment risk is retired and the binary readout remains the sole remaining catalyst.
- 2026-10-09 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - Millennium Doubles Down Millennium grew its stake ~73% to 8.7% during the dead-money drift and before enrollment news, reinforcing institutional conviction in the mid-2027 binary event.
- 2026-11-06 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - Homework Done, Stock Down 28% ATM unused for a third straight quarter, burn slowed to ~$10M, runway language upgraded back to 'well through' topline, and Hybrid CATT1 started — operational checklist is cleaner despite the 28% price drop.
- 2026-11-17 Speculative buy speculative UPDATE: vTv Therapeutics (VTVT) - A Seller Who Had No Choice Samsara's block sale was a forced LP-redemption event, not a discretionary exit; the fund retained ~98% of its economic position and the clinical story is unchanged.
- Long call · opened Feb 4, 2026 at $36.41 · -52.5% vs XBI +16.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“A total of 166 patients were randomized in the study and the Company expects to report topline results from the CATT1 study in mid-2027.”
matched to CATT1 (Phase 3) · topline data
-
-
-
““Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics.”
matched to CATT1 (Phase 3) · topline data
-
-
-
“We expect to initiate a Phase 2 study in patients with T1D using hybrid closed loop insulin infusion systems in late 2026.”
matched to CATT1 (Phase 3) · topline data / matched to Cadisegliatin (T1D) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026SCHEDULE 13D/A13D amendment→ BD updateSamsara BioCapital — a specialist healthcare VC led by Dr. Srinivas Akkaraju — filed a Schedule 13D/A disclosing a ~9.9% beneficial stake in VTVT, including a November 12 block sale of 61,287 shares at $17.60 that looks like selling but was legally a redemption trade with no economic impact on Samsara's own position; the 13D designation (not passive 13G) and the stock's 18.6% slide since the last update make this worth unpacking for subscribers.
- Nov 5, 2026ReleasevTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updatevTv's Q3 print arrives with VTVT down ~28% from early October — the stock's slide predates tonight's release, and three of the most watched variables (ATM, cash runway, timeline) are mostly holding, though a CFO 10b5-1 plan and a quiet G42 timeline slip deserve attention.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 27, 2026ReleasevTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Syste
- Oct 10, 2026ReleasevTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
- Oct 7, 2026ReleasevTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseBD extracted 1 program update from this document → VTVT pipeline
- Oct 6, 2026ReleasevTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
- Oct 6, 20268-KCurrent report: charter / bylaws / fiscal year
- Oct 5, 2026ReleasevTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)→ BD updatevTv just confirmed CATT1 enrollment is complete — 166 patients randomized, on the Q3 2026 schedule promised three quarters running. The bet-the-company readout is now locked in for mid-2027, and the clock is officially ticking.
- Sep 2, 2026ReleasevTv Therapeutics to Participate in September Investor Conferences
- Aug 6, 2026ReleasevTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jun 29, 20268-KCurrent report: shareholder vote
- Jun 10, 2026DEFA14AProxy soliciting material
- May 13, 2026ReleasevTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 20268-KCurrent report: other events
- May 13, 2026424B2Prospectus supplement
- May 13, 202610-QQuarterly report
- May 7, 2026ReleasevTv Therapeutics to Participate in Upcoming May Investor Conferences
- Apr 28, 2026DEF 14AProxy statement
- Mar 10, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 10, 20268-KCurrent report: results of operations · EX-99.1
- Mar 10, 202610-KAnnual report
5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 8, 2026SCHEDULE 13G/A13G amendment→ BD updateMillennium Management quietly grew its VTVT stake from 5.0% to 8.7% — adding 144,244 shares through the ATM scare, the enrollment delay, and the dead-money drift — and the market hasn't priced it yet.
- Jul 29, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026S-8Employee plan registration
- Apr 16, 2026SCHEDULE 13G/A13G amendment
- Mar 27, 2026SCHEDULE 13GPassive >5% holder (13G)